• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

1.0 LPBI – 2012-2020 VISTA

2020 VISTA is the Website for LPBI Group’s Ten Health Care Contents Asset Classes prospected for technology ownership transfer and monetization

6/3/2022

We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022

https://pharmaceuticalintelligence.com/2022/04/25/we-celebrate-ten-years-of-excellence-lpbi-group-4-2012-4-2022/

 

2022 Update from LPBI Group | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/

  • 1.0 LPBI IP Asset Class I: Journal Articles by Top Authors

Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors)(c) Total Articles Views and (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views (e) External Citations

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/2022/04/11/equity-sharing-calculation-a-scoring-system-for-authors-a-total-articles-single-author-and-multiple-authorsb-total-articles-views-and-c-authors-proportion-of-own-articles-views-in/

 

  • LinkedIn 1st degree connections by Biotech Company Name and by Connections positions

Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025

and

Data Scientist, Research Assistant III: Tianzuo George Li

https://pharmaceuticalintelligence.com/2022/04/04/analytics-for-e-reputation-based-on-linkedin-1st-degree-connections-7500-of-lpbi-groups-founder-2012-2022-an-intangible-asset-connections-position-seniority-biotech-pharma-focus/

8/20/2021

2.0 LPBI is a Very Unique Organization 

Portfolio of IP Assets: 2012-2025

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

Pipeline Products, 2021-2025 beyond 1.0 Ten IP Asset Classes:

2.0 LPBI comprise of the following four IP Asset Classes: XI, XII, XIII, XIV

IP Asset Class XI (Queries yielding results on the Fly) – ending up in Blockchain storage available for monetization as a new product

  • New Digital Products as a result of Discovery 💡 of new digital products derived from and created for the new queries by users to be generated on the fly not in existence in the knowledge graph database

IP Asset Class XIV (Mission #1) – 2.0 LPBI all Products of NLP, yields for Mission #1: Generated NLP Results to be hosted on the blockchain, new to be generated by the interface of the blockchain and ML, NLP and value added creation for IP Asset Class XI – synergy between existing and new discovery

  • We completed Medical Text analysis with NLP for Cancer Volume 1 – will be published as New Genre Book in 2022
  • We completed Medical Text analysis with NLP for Genomics Volume 2 – will be published as New Genre Book in 2022

In addition, all new Digital Products of Mission #3 and Mission #4 will be stored on the Blockchain IT Infrastructure (Mission #2)

IP Asset Class XIV (Mission #2) – Blockchain schema: Knowledge graphs and edges mapping the Ontology

  • All digital products of Mission #2: Content Monetization on a Blockchain IT Platform, i.e., interface to NLP

IP Asset Class XII (Mission #3) – ending up in Blockchain storage available for monetization transactions as new products

  • All digital products of Mission #3, below: New Genre of Scientific Books N =18, see book architecture, below,

IP Asset Class XIII (Mission #4) – ending up in Blockchain storage available for monetization transactions as new products

  • All digital products of Mission #4, below: New therapeutics molecules generated for 12 Galectins by Synthetic Biology software

 

 

2/1/2021

Milestone achieved today:

February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical 

https://pharmaceuticalintelligence.com/2021/02/01/february-1-2021-we-celebrate-1924400-e-readers-6000-scientific-journal-articles-7525-scientific-comments-a-journal-ontology-of-728-medical-life-sciences-research-categories-10440-tag/

Thought on the transition

One Possible Strategy for an Acquisition is via a SPAC

https://pharmaceuticalintelligence.com/2021/02/01/february-1-2021-we-celebrate-1924400-e-readers-6000-scientific-journal-articles-7525-scientific-comments-a-journal-ontology-of-728-medical-life-sciences-research-categories-10440-tag/

Follow the links

  1. Executive Summary
  2. Opportunities Map in the Acquisition Arena
  3. Dynamic Contents for LPBI Group’s PowerPoint Presentation
  4. Detailed Technology Description
  5. Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
  6. Top Authors by Number of eReaders Views
  7. Top Articles by Number of e-Readers for All Days ending 2019-02-17
  8. LPBI Group’s Social Media Presence
  9. Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
  10. Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
  11. Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class 
  12. Financial Advisory & Legal Advisory Providers: US & Israel
  13. Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
  14. FIT Members Contribute to Opportunities Map
  15. FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lapsing of Active Status, COMPs Formulas
  16. Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
  17. LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
  18. FIT members – Who works on WHAT?
  19. Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
  20. MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
  21. JOURNAL Statistics on 2/24/2019
  22. Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
  23. Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
  24. REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI
  25. 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis 
  26. Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN
  27. 2020/2021 LPBI Plan for IT Projects & Research Projects – LPBI’s TASKS for Research Assistants & Associates
  28. LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present
  29. WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019
  30. For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets
  31. The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation
  32. e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views=Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW
  33. Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers  

9/25/2020

1.0 & 2.0 LPBI Group’s Team

  • Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
  • Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
  • Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
  • Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group
  • Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
  • Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases
  • Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery
  • Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications
  • Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML

8/19/2020

An UPDATE Shared with ALL

We launched on 3/14/2020 the Coronavirus PORTAL https://pharmaceuticalintelligence.com/coronavirus-portal/ which covers 8 topics:

  • Breakthrough News Corner
  • Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus
  • An Epidemiological Approach Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN Lead Curators – e–mail Contacts: sjwilliamspa@comcast.net and avivalev-ari@alum.berkeley.edu
  • Community Impact Stephen J. Williams, PhD and Irina Robu, PhD Lead Curators – e–mail Contacts: irina.stefania@gmail.com and sjwilliamspa@comcast.net
  • Economic Impact of The Coronavirus Pandemic Dr. Joel Shertok, PhD Lead Curator – e–mail Contact: jshertok@processindconsultants.com
  • Voices of Global Citizens: Impact of The Coronavirus Pandemic, Gail S. Thornton, M.A. Lead Curator – e–mail Contact: gailsthornton@yahoo.com
  • Diagnosis of Coronavirus Infection by Medical Imaging and Cardiovascular Impacts of Viral Infection, Aviva Lev-Ari, PhD, RN Lead Curator e-mail contact: avivalev-ari@alum.berkeley.edu
  • Key Opinion Leaders Followed by LPBI Aviva Lev-Ari, PhD, RN and Dr. Ofer Markman, PhD Lead Curators e-mail contacts: oferm2015@gmail.com and avivalev-ari@alum.berkeley.edu

That effort took 2 months of most intensive work on my part.

STATEMENT

  • The economic impact of of the Pandemic DOES HAVE A NEGATIVE EFFECT ON THE M&A MARKET
  • In the INTERIM awaiting for more favorable conditions on the market
  • we invested in INTERNAL development of IP

We launched FOUR additional PORTALS:

  • Artificial Intelligence in Genomics & Cancer 

https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/

  • 2020 Summer Internship Portal

https://pharmaceuticalintelligence.com/2020-summer-internship/

  • Knowledge PORTALS System (KPS) @LPBI 

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/ 

  • 2021 Medical Text Analysis (NLP)

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

  • As an ADJUSTMENT for submitting the documentation to the Investment Banker in 10/2020 vs the original plan 4/2020, we are working on
  • The Plan for 2021 – 2025. It involves six new strategies: TNS #1,2,3,4,5,6

TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

Phase 1: Natural Language Processing(NLP) – 24 months FREE Microsoft AZURE for Health

Phase 2: Piloting the Proof of Concept on 4 of LPBI BioMed 16 volumes:

  • Cancer, Volume 1 & 2 and Genomics, Volume 1 & 2

Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:

  • The Wolfram Solution for Biological Sciences
  • The Wolfram Data Drop

TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA 

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL 

TNS #5: Joint venture with Dr. Nir for Drug Discovery:

TNS #6:  e-Books Translations into Japanese, Spanish, Russian

 

These are two distinctive entities

2.0 LPBI, 1/2021 – 12/2025 – TNS #1,2,3,4,5,6, above. Executive Summary

https://pharmaceuticalintelligence.com/leaders-in-pharmaceutical-business-intelligence/

1.0 LPBI, 4/2012 – 12/2020 – Executive Summary 

https://pharmaceuticalintelligence.com/home-website-front-page/

Cumulative Revenue Potential PREDICTION of Journal Articles: Under Two Growth Assumption Regimes and Two Prediction Models

RED & BLUE Lines

A. Rate of Articles published in 2021-2025 is trending 2017, 2018, 2019, 2020 

RED Line – A Marked Point Process Model:  $48MM for Journal Valuation 

BLUE Line – A Conservative Assumption-based Growth Prediction (Joel)

vs

BROWN & GREEN Lines 

B. No New Articles after 12/2020 will be published

BROWN Line – A Marked Point Process Model – Assuming Last article published on 12/31/2020

GREEN Line –  A Conservative Assumption-based Growth Prediction (Joel) – Assuming Last article published on 12/31/2020

Data Source: 

WordPress.com Web Statistics of 1.8 Million Views of 6,000 Scientific Articles, 6/30/2020

[for the Annual 2020 data: the first 6 months x2].

4/2012 – 12/2020 – ACTUALS 

2021 – 2025 – FORECAST 

Our 1.0 LPBI portfolio of Intellectual Property (IP) include TEN asset classes

UPDATED on 8/20/2021

To these TEN IP Asset Classes – add THREE IP Asset Classes by 2.0 LPBI

2.0 LPBI is a Very Unique Organization 

2.0 LPBI all Products of NLP, see Yields for Mission #1, above

PLUS Pipeline Products, 2021-2025 beyond 1.0 Ten IP Asset Classes: XI, XII, XIII

IP Asset Class XI (Queries yielding results on the Fly) – ending up in Blockchain storage available for monetization as a new product

  • New Digital Products as a result of Discovery 💡 of new digital products derived from and created for the new queries by users to be generated on the fly not in existence in the knowledge graph database

In addition, all new Digital Products of Mission #3 and Mission #4

IP Asset Class XII (Mission #3) – ending up in Blockchain storage available for monetization transactions as new products

  • All digital products of Mission #3, below: New Genre of Scientific Books N =18, see book architecture, below,

IP Asset Class XIII (Mission #4) – ending up in Blockchain storage available for monetization transactions as new products

  • All digital products of Mission #4, below: New therapeutics molecules generated for 12 Galectins by Synthetic Biology software
LPBI portfolio of Intellectual Property (IP) include TEN asset classes

Asset Classes

Type

Quantity

Asset Class I The Journal 6,067 articles on 7/9/2021
Valuation [$XXMM] See Excel
7/9/2021 Views 2,007,056
Asset Class II BioMed e-Series 18 volumes
https://pharmaceuticalintelligence.com/2019-vista/global-market-penetration-forecast-for-each-volume-in-the-16-volume-biomed-e-series/ Valuation [$5M] done by Joel & Aviva
July 2021  128,000 page downloads in total on 7/2021. This number represents the equivalent of 64 books to have been sold [KENP to Book]
Asset Class III eProceedings 100 events
https://pharmaceuticalintelligence.com/2019-vista/e-proceedings-and-tweet-collections-per-conference-2013-2020-viewsdownloads-x-100-real-time-coverage-of-60-events-by-ala-sjw/ Valuation [$1.4M] done by Dr. Williams & Aviva [does not include Tweet Collection N = 40 needs Updated from 2019-2021
Asset Class IV Platform, composition of methods and workflows for the content creation of scientific curations. See Platform:  $6MM
Coronavirus PORTAL covers 8 topics launched on 3/14/2020
https://pharmaceuticalintelligence.com/coronavirus-portal/
ArtificiaI Intelligence in Genomics & Cancer Portal for Text Analysis of Journal articles and Books in these two domains by NLP, ML and AI algorithms
https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/
2020 Summer Internship Portal
https://pharmaceuticalintelligence.com/2020-summer-internship/
Knowledge PORTALS System (KPS) @LPBI
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/ 
2021 Medical Text Analysis (NLP)
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
Asset Class V Gallery of Biological Images in use in Articles and Books 6,000 Biological images in the Journal’s Media Gallery
Asset Class VI Team of Experts  BIOs Final Improvement Team (FIT) aka LPBI US  and LPBI India
See Portal Platform: $3MM
•    Knowledge Platform System (KPS)
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/ New Organizational Chart

[w-i-p]

Asset Class VII Royalties on BioMed e-Series:Page downloads, Book borrowings and Book sale July 2021  145,000 page downloads in total on 7/21/2021.

This number represents the equivalent of 70 books to have been sold [KENP to Book]

Asset Class VIII Subscribers to the Website 2,641 on 7/9/2021
Asset Class IX INTANGIBLE ASSETS & Intrinsic Value = Good Will  TBD
Asset Class X e-VOICES                       PODCASTING            Audio Library  A Podcast is shared FREE as industry standard, Entire Podcast Libraries commend a price
e-VOICES Podcasting, 2019 – 2021 Podcasts on LPBI Leaders. 7/2021 a Library of Podcasts is developed for “Interviews with Scientific Leaders”    N = +280 podcasts

 

We estimate revenue potential of each entity to be

~~ $XX Million for 1.0 LPBI [Above Ten IP Asset Classes]

  • Graph above present the Valuation of IP Asset Class I 

~~ $XX Million for 2.0 LPBI [Excel Sheet for Financial Projection was developed in 8/2020]

~~ $ XXX Million for 1.0 LPBI plus 2.0 LPBI

The feedback that we will get from the Investment Banker will guide the TIMING and the Strategy 

  • ALL ACTIVE Member of the Final Improvement Team (FIT) on record for the EXIT will be in constant communication regarding all of the above
  • Personal PORTAL for each member of FIT is displayed on https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
  • Meg Baker is considering a collaboration in the JOINT VENTURE (LPBI X%) and Dr. Raphael Nir (7X%) on Galectins & Synthetic Biology in Drug Discovery
  • Our Podcast Library is growing – See Table, below

Development Plan for e-VOICES Podcasting, 2019 – 2021*

https://pharmaceuticalintelligence.com/audio-podcasts/

Podcast Interviewer INTERVIEWEE(S) Subject Date Audio/Video/

Narrator

         
TBD Dr. Stephen J. Williams, Dr. Irina Robu & Dr. Aviva Lev-Ari 3D BioPrinting in Medicine 5/2019 Audio
Gail S. Thornton Prof. Feldman Evolution Biology and Population Genetics 3/17/2020 Audio
Gail S. Thornton Dr. Larry H. Bernstein, MD, FCAP Life Memoirs in Clinical Pathology Told 10/12/2020 Audio

Narrator:

Dr. S.J. Williams

Gail S. Thornton Dr. Sudipta Saha Research in Reproductive Technology 11/7/2020 Audio
 TBD Dr. Justin D. Pearlman, MD, PhD Cardiac Imaging – Evolution of Diagnostic Methods 4Q 2020 Audio
TBD Dr. Raphael Nir From Big Pharma to Biotech Entrepreneurship 2021 Audio
TBD Dr. Meg Baker GlycoBiology in Practice 2021 Audio
TBD Dr. Ofer Markman Memories of

Procognia

2021 Audio
TBD Dr. Irina Robu AI & Tissue Engineering 2021 Audio
TBD Dr. Williams Preferably 3rd party interviewer sourced by Gail. Topic: AI & Genomics 2021 Audio
TBD Dr. Aviva Lev-Ari Preferably 3rd party interviewer sourced by Gail. Topic: Curation & ML 2021 Audio

Schedule for 2021 Newsletters posted  https://pharmaceuticalintelligence.com/newsletter/

DETAILS about IP Asset Class I: LPBI Journal, IP Asset Class II: BioMed e-Series and IP Asset Class III: Biotech & Medical Conference e-Proceedings and Tweet Collections

Our VAST intellectual property (IP) portfolio includes three asset classes:

  • IP Asset Class I: LPBI Journal

https://lnkd.in/eEw5q7N

+1.8Million eReaders, +5900 scientific articles, +700 categories of research

  • IP Asset Class II: BioMed e-Series

https://lnkd.in/ekWGNqA

16 Volumes in Medicine

What make our e-Books UNIQUE: An Example

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology. Published on 12/28/2019

  • No other book covers the same topics in a single volume. In terms of synergy, this book combines:
    1. Content curation in article format with embedded videos and audio podcasts
    2. Conference e-Proceedings based on real-time coverage by the authors and editors of this book.
    3. Archived tweets of quotes from speakers at leading Biotech conferences, posted in real-time by the same authors
  • It integrates in a single volume four distinct perspectives: (a) basic science, (b) technologies & methodologies, (c) clinical aspects, and (d) business and legal aspects.
  • The material in this book represents the scientific frontier in Biological Sciences and Medicine related to the Genomics aspects of Disease Onset. It addresses:
    1. All aspects of life: the Cell, the Organ, the Human Body and Human Populations
    2. All methodologies of genomic data analysis: Next Generation Sequencing, Gene Editing, AI, Single Cell Genomics, Evolution Biology Genomics, Simulation Modeling in Genomics, Genotypes and Phenotypes Modeling, measurement of Epigenomics effects on disease, and developments in Pharmaco-Genomics
  • Artificial Intelligence in Medicine is covered in Part 3 of the e-Book. 3.1 to 3.5 represent the frontier in this emerging field:

    3.1 The Science

    3.2 Technologies and Methodologies

    3.3 Clinical Aspects

    3.4 Business and Legal

    3.5 Latest in Machine Learning (ML) Algorithms harnessed for Medical Diagnosis: Pattern Recognition & Prediction of Disease Onset

  • No other book incorporates 74 e-Proceedings created in real time by the Book’s authors and editors
  • No other book incorporates four collections of Tweets representing quotes from speakers at global leading conferences on Genomics
  • No other book has 13 locations of Videos and Audio Podcasts that serve to enrich the e-Reader’s experience
  • No other book has 326 articles on the topics included in the Book’s title: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
  • IP Asset Class III: Biotech & Medical Conference e-Proceedings

https://lnkd.in/dc2qGAK

Corpus of 70 events covered in real time yielding 60 e-Proceedings and 36 Tweet Collections

OTHER ASSET CLASSES: IV, V, VI, VII, X

  • Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations
  • Asset Class V is a Gallery of 5,100 images used in the articles and books
  • Asset Class VI is the Team of Experts
  • Asset Class VII are the Royalties on BioMed e-Series:
  1. e-Book age down loads,
  2. e-Book borrowings and
  3. e-Book sale
  • Asset Class X are the e-Voices Podcasting – Audio Podcasts Library https://pharmaceuticalintelligence.com/audio-podcasts/

Asset List showing Value:

@@@@@ TANGIBLE ASSETS:

1. The Journal has 1,829,736 eReaders on 9/25/2020 – ASSET CLASS I

— It has +5900 articles 

— It demonstrates > 7500 comments by Scientists for +5900 articles 

— It has +10K tags counted by the computer

— It has +700 categories of research in SIX disciplines among them the most complex are

  • Cell signaling
  • ATP
  • Autophage
  • Computational Biology and NGS
  • Cardiac imaging
  • Endosome
  • Liposomes

— It has 2,549 subscribers on 8/18/2020

2. The BioMed e-Series – ASSET CLASS II

Royalties structure:

– 121,547 page downloads in total on 8/31/2020

– x book borrowing

– y book sale – suppressed by Unlimited Prima Membership: READ FOR FREE and Pay per view 

– 65% of book sales revenues is retained by Amazon

3. e-Proceedings and Activity on Twitter.com – ASSET CLASS III

  •  LPBI is the One and only e-Proceedings generator at end of Conference by one-Click
  • The #WMIF19 Influencers via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19– By Mentions and By Tweets Ranked #4: @pharma_BI and Ranked #2: @AVIVA1950, respectively. Ranked #3 via @NodeXL Betweenness Centrality http://bit.ly/2KB6cPN
  • For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] 
  • https://analytics.twitter.com/user/AVIVA1950/tweets

@@@@@ INTANGIBLE ASSETS equal e-Reputations

A. Institutions following @AVIVA1950 and @pharma_BI include the marque organizations as follows:

  • TECHNION
  • WEIZMANN INSTITUTE
  • HEBREW UNIV
  • PARTNERS INNOVATIONS: MGH & BWH
  • BROAD INSTITUTE  @MIT & @Harvard
  • Bayer US
  • PhRMA
  • Keck Medicine of USC
  • Intermountain Cancer
  • MassBio
  • Hadasit Bio Holdings
  • BioWorld
  • Bell Labs
  • BCM_CVRI
  • MIT Spectrum
  • TED Talks

B. LPBI’s Founder is followed by 500 CEOs 200 CEOs in Biotech & Pharma on LinkedIn and

C. LPBI’s Founder has ~7300 followers 1st level connection on LinkedIn.

Distribution of 1st level LinkedIn connection by Industry

Chemicals 2366
Pharmaceuticals 919
Biotechnology 841
Oil & Energy 664
Staffing and Recruiting 218
Management Consulting 218
Research 207
Information Technology and Services 198
Environmental Services 183
Plastics 171
Food & Beverages 137
Marketing and Advertising 115
Human Resources 96
Food Production 93
Financial Services 92

D. LPBI’s Founder is bestowed by >1000 endorsements 

@@@@ LPBI Group’s Social Media Presence in 2020

Our Social Media Presence in 2020 is by two handles on Twitter.com

@pharma_BI 

Official handle of my Venture: Leaders in Pharmaceutical Business Intelligence (LPBI) Group,

Boston, MA, NJ, CA, PA, ME, DE, India, Israel & Canada

  • Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers  
  • LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
  • MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
  • Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019

@AVIVA1950

Personal account of Aviva Lev-Ari, PhD, RN – LPBI Group’s Founder

2019 World Medical Innovation Forum on AI in Medicine – Aviva’s rankings as Influencer

  • The #WMIF19 Influencers via @symplur‘s #HealthcareHashtags http://bit.ly/WMIF19– By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

  • For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets
  • The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation
  • Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
  • Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
  • Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN

Follow the links

  1. Executive Summary
  2. Opportunities Map in the Acquisition Arena
  3. Dynamic Contents for LPBI Group’s PowerPoint Presentation
  4. Detailed Technology Description
  5. Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
  6. Top Authors by Number of eReaders Views
  7. Top Articles by Number of e-Readers for All Days ending 2019-02-17
  8. LPBI Group’s Social Media Presence
  9. Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
  10. Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
  11. Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class 
  12. Financial Advisory & Legal Advisory Providers: US & Israel
  13. Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
  14. FIT Members Contribute to Opportunities Map
  15. FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lapsing of Active Status, COMPs Formulas
  16. Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
  17. LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
  18. FIT members – Who works on WHAT?
  19. Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
  20. MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
  21. JOURNAL Statistics on 2/24/2019
  22. Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
  23. Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
  24. REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI
  25. 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis 
  26. Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN
  27. 2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates
  28. LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present
  29. WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019
  30. For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets
  31. The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation
  32. e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views=Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW
  33. Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers  

Our Team

  • Aviva Lev-Ari, PhD, RN, Director and Founder
  • Members of the Board
  • Senior Editors
  • Experts, Authors, Writers (EAWs)
  • Business Development & Private Equity Investment
  • Scientific Delegation Members & Patent Holders
  • Inventors: Biologics
  • Inventors: Medical Devices
  • Research Assistants
  • Research Associates

1.0 & 2.0 LPBI Group’s Team

  • Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
  • Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
  • Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
  • Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group
  • Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
  • Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases
  • Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery
  • Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications
  • Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

This page has the following sub pages.

  • Executive Summary
  • Opportunities Map in the Acquisition Arena
  • Dynamic Contents for LPBI Group’s PowerPoint Presentation
  • Detailed Technology Description
  • Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
  • Top Authors by Number of e-Readers Views as of 2020-06-02
  • Top Articles by Number of e-Readers for All Days ending 2020-06-02
  • LPBI Group’s Social Media Presence
  • Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
  • Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
  • Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class 
  • Financial Advisory & Legal Advisory Providers: US & Israel
  • Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
  • Final Improvement Team (FIT) Members Contribute to Opportunities Map & Define LPBI Uniqueness
  • FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lasping of Active Status, COMPs Formulas
  • HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
  • LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
  • Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
  • MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
  • FIT members – Who works on WHAT?
  • Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers  
  • JOURNAL Statistics from Inception, Data retrieved on 2/24/2019
  • e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views = Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW 
  • Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
  • Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
  • REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI
  • 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis 
  • Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN
  • LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present
  • WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019
  • 2021 LPBI Plan for IT Projects & Research Projects – LPBI’s TASKS for Research Assistants & Associates

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,254 other subscribers
  • Recent Posts

    • Press Release for Five Bilingual BioMed e-Series January 29, 2023
    • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
    • Verily announced other organizational changes, 1/13/2023 January 16, 2023
    • Mission 4: Use of Systems Biology for Design of inhibitor of Galectins as Cancer Therapeutic – Strategy and Software December 13, 2022
    • Science Has A Systemic Problem, Not an Innovation Problem December 12, 2022
    • Chemistry Nobelist Carolyn Bertozzi’s years at UC Berkeley October 24, 2022
    • Technion #1 in Europe in Field of AI for 2nd Straight Year October 20, 2022
    • Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners October 11, 2022
    • The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells October 11, 2022
    • Cancer Policy Related News from Washington DC and New NCI Appointments October 4, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


 

Loading Comments...
 

    %d bloggers like this: